We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.
This gives us the potential to revolutionise how people think about brain health and disease management.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
A huge thanks to Dr Catherine Mummery for taking the OBD team through an extensive tour of the novel approaches in #dementia We found the discussions and the Q&A interactions insighful. The future looks incredibly promising and taking into account the developments in gene therapy is to be noted and kept a very close eye on.
Cortical Disarray Measurement (CDM) has been appointed as a secondary outcome measure for a Randomized, Placebo, Controlled, Double-Blind Study of XPro™ in Patients with Mild Alzheimer’s Disease with Biomarkers of Inflammation. The trial sponsor is INmune Bio, a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that harness the patient’s innate immune system to fight disease.
It was our pleasure to host and listen to Professor Malú Gámez Tansey at the Oxford Brain Diagnostics guest speaker series. Prof Tansey is currently Director of the Center for Translational Research in Neurodegenerative Disease (CTRND) and the first endowed Norman and Susan Fixel Chair in Neuroscience and Neurology at University of Florida. A very insightful dicussion into the contrbution neuroinflammation has in parkinson's disease. In addtion, research was shared on the role of the gut brain axis in PD.
Professor Craig Ritchie is currently Professor of Psychiatry of Ageing at the University of Edinburgh. He is also Director at Brain Health Scotland, a non for profit organisation on a mission to inspire and empower you to protect your brain health and reduce your risk of diseases that lead to dementia. A wonderful discussion was had on Brain Health issues, early diagnosis and tracking patient outcomes with smart biomarkers.